OTC · BMYMP
Healthcare · Drug Manufacturers - General
$400.00
Down-$540.22 (-57.46%)
Updated Sep 22, 2026, 2:00 AM
SID Score
6.8/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BMYMP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BMYMP.
BMYMP research
Company profile and research snapshot.
BRISTOL-MYERS SQUIBB $2PR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Piper Sandler | Overweight | — |
| Sep 10, 2026 | HSBC | Hold | — |
| Aug 5, 2026 | Argus Research | Buy | — |
| Aug 3, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Mar 24, 2026
AQRâs Q4 2025 13F: $191B portfolio led by Nvidia plus Apple, Microsoft, Alphabet & Amazon, with selective diversification. See more details here.
Yahoo · Mar 9, 2026
Bristol Myers wins FDA approval to expand Sotyktu for psoriatic arthritis after strong POETYK study data, adding a new indication for the TYK2 inhibitor.
Yahoo · Mar 9, 2026
The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs Revlimid and Pomalyst.
Yahoo · Mar 9, 2026
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Interpretive context generated from the platform’s current data sources.
Bristol-Myers Squibb's convertible preferred series BMYMP currently trades at $400.00 per share, per SID market data, reflecting a notably low-volatility profile with a beta of just 0.30, indicating the security moves roughly one-third as much as the broader market. Average daily volume stands at approximately 5 shares, according to Massive/Polygon data, underscoring the extremely thin liquidity characteristic of convertible preferred instruments. This illiquidity means that even modest buy or sell orders can produce outsized price movements. The underlying company carries a market capitalization of approximately $1.82 trillion across all share classes, positioning it among the largest healthcare entities globally. The preferred series offers a dividend yield of approximately 4.84%, per SID market data, which provides a meaningful income component relative to common equity. The low beta and elevated yield together suggest this instrument functions primarily as an income-oriented security within the Bristol-Myers capital structure.
Bristol-Myers Squibb's convertible preferred shares reflect underlying company valuation metrics that position the healthcare giant at a price-to-earnings ratio of 17.28, per SID market data, which sits broadly in line with large-cap pharmaceutical peers. The PEG ratio of 0.90, according to SID market data, suggests the stock may be attractively valued relative to its expected earnings growth rate, as readings below 1.0 generally indicate growth is not fully priced into the current valuation. The price-to-book ratio stands at 5.62, per SEC filings, reflecting significant intangible asset value typical of pharmaceutical companies with substantial intellectual property portfolios. The preferred series carries a dividend yield of 4.84%, meaningfully above the healthcare sector average, providing compensation for the instrument's limited liquidity. Within the broader healthcare sector, these valuation metrics suggest the underlying Bristol-Myers common equity trades at a moderate premium to book value while maintaining reasonable earnings-based multiples.
Institutional and insider positioning in Bristol-Myers Squibb's convertible preferred shares reflects a neutral overall stance, with the composite smart money score registering at 46 out of 100, per SID market data, generating a neutral signal. Breaking down the component scores reveals a mixed picture across tracking categories. Insider activity scores 12.5 out of 25, according to SEC Form 4 filings, indicating neither aggressive accumulation nor notable distribution by corporate officers and directors. Institutional ownership scores 13.0 out of 25, per 13F institutional filings, reflecting moderate but not outsized positioning by large fund managers. Dark pool activity registers at 8.5 out of 25, the weakest component, suggesting limited off-exchange institutional block trading in this thinly traded preferred series. Congressional trading activity scores 12 out of 25, showing no meaningful directional bias from disclosed legislative branch transactions. The aggregate data indicates that sophisticated market participants are maintaining a wait-and-see posture on BMYMP, with no component category showing conviction-level scores in either direction.
No recent earnings data specific to the BMYMP convertible preferred series is currently available in the reporting database. However, the underlying Bristol-Myers Squibb common equity's financial performance directly impacts the preferred instrument's conversion value and dividend sustainability. The company's trailing price-to-earnings ratio of 17.28, per SID market data, implies annual earnings power that supports the preferred series' 4.84% dividend yield. The PEG ratio of 0.90, according to SID market data, indicates that consensus analyst growth expectations remain constructive relative to the current earnings multiple, suggesting forward earnings trajectory could support continued preferred dividend coverage. As a healthcare sector entity with significant pharmaceutical revenue streams, Bristol-Myers Squibb's earnings cadence follows standard quarterly reporting cycles. Investors in the convertible preferred series should monitor the parent company's earnings releases closely, as any material deterioration in common equity earnings could affect both dividend payments and conversion economics for BMYMP holders.
Recent Wall Street coverage of Bristol-Myers Squibb reflects a moderately constructive consensus, with the most recent analyst actions spanning from July through September 2026. Piper Sandler reiterated an Overweight rating on September 16, 2026, per Wall Street analyst reports, maintaining a positive stance on the company's prospects. Argus Research upgraded the stock to Buy from Hold on August 5, 2026, representing the most notable shift in sentiment during the review period, according to SID consensus data. Guggenheim maintained its Buy rating on July 31, 2026, while Citigroup maintained a Neutral position on August 3, 2026. HSBC reiterated a Hold rating on September 10, 2026. Of the five most recent analyst actions, two carry Buy-equivalent ratings, two maintain Hold-equivalent stances, and one holds an Overweight designation, producing a distribution that leans modestly positive. No analyst issued a Sell or equivalent downgrade during this period, suggesting a floor of confidence in Bristol-Myers Squibb's fundamental outlook.
The latest Smart Investors Daily articles mentioning BMYMP.
